3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
18
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Adenocarcinoma
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Cancer
1
Sarcoma
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy
1
Lip Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Invasive Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA